Date: 2016-04-14
Type of information: Nomination
Compound:
Company: Kymab (UK)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On April 14, 2016, Kymab, the Cambridge-based antibodies-to-medicines company, announced that it has strengthened its management team with three appointments to head up its key therapeutic areas. Professor Paul Kellam will lead Kymab’s initiatives in vaccines & infectious disease,Professor Igor Theurl will lead the discovery of medicines for blood diseases and Matthew McCourt will head up immuno-oncology. Kymab has defined these three areas as a key focusfor its strategy to develop new medicines and vaccines in areas of unmet clinical need.
Professor Paul Kellam, Vice-President of Vaccines & Infectious Disease has a distinguished career in virology and published over 175 articles, having worked at the Wellcome Trust Sanger Institute, where his team uncovered a crucial human genetic variant that affects the outcome of influenza infection. He is an internationally recognised expert in examining the genomes of emerging infectious disease, such as Ebola and the MERS coronavirus as well as HIV and other virus infections. In addition to his role with Kymab, Professor Kellam serves as part-time Professor of Virus Genomics at Imperial College London.
Professor Igor Theurl, Head of Haematology, is a board-certified practicing physician and experimental scientist whose work includes the area of anaemia of chronic disease and has published more than 60 articles. Alongside his leadership role with Kymab, Professor Theurl will serve part-time as Professor of Medicine at the University of Innsbruck, Austria.
Matthew McCourt, Vice-President of Immuno-oncology, has been promoted internally having joined Kymab in 2015. He brings 25 years’ experience in biopharmaceutical research and development. Previous experience includes, roles as Director of Oncology Biology at MedImmune, where his team drove the discovery and preclinical development of MedImmune’simmuno-oncology portfolio of biologics and Head of Pharmacology at Cambridge Antibody Technology.
Financial terms:
Latest news:
